Literature DB >> 26899258

Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.

Akinobu Taketomi1.   

Abstract

Angiogenesis is a promising therapeutic target to inhibit tumor growth. This review summarizes data from clinical trials of antiangiogenic agents in hepatocellular carcinoma. A systematic search of PubMed was performed to identify clinical trials of specific antiangiogenic agents in hepatocellular carcinoma treatment, particularly phase III trials involving treatment guidelines for advanced hepatocellular carcinoma. Sorafenib is the only systemic drug approved for the treatment of advanced hepatocellular carcinoma. Two large-scale, randomized phase III trials using sorafenib involving patients with unresectable HCC showed a significant survival benefit compared with placebo control groups. However, subsequent phase III trials of antiangiogenic agents in hepatocellular carcinoma have failed to improve survival compared with standard treatment protocols using sorafenib. The efficacy of antiangiogenic agents in combination with other drugs, transarterial chemoembolization, and surgical resection is currently being investigated. Future research is expected to optimize antiangiogenic therapies in combination with standard treatment with sorafenib.

Entities:  

Keywords:  Angiogenesis; Antiangiogenic therapy; Hepatocellular carcinoma; Sorafenib

Mesh：

Substances：

Year:  2016        PMID： 26899258     DOI： 10.1007/s10147-016-0966-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN： 1341-9625            Impact factor:   3.402


  41 in total

1.  Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).

Authors:  Dieter Koeberle; Michael Montemurro; Panagiotis Samaras; Pietro Majno; Mathew Simcock; Andreas Limacher; Stefanie Lerch; Katalin Kovàcs; Roman Inauen; Vivianne Hess; Piercarlo Saletti; Markus Borner; Arnaud Roth; György Bodoky
Journal:  Oncologist       Date:  2010-03-04

2.  Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation.

Authors:  Akinobu Taketomi; Takasuke Fukuhara; Kazutoyo Morita; Hiroto Kayashima; Mizuki Ninomiya; Yoichi Yamashita; Toru Ikegami; Hideaki Uchiyama; Tomoharu Yoshizumi; Yuji Soejima; Ken Shirabe; Yoshihko Maehara
Journal:  Ann Surg Oncol       Date:  2010-03-05       Impact factor: 5.344

Review 3.  New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.

Authors:  Makoto Chuma; Katsumi Terashita; Naoya Sakamoto
Journal:  Hepatol Res       Date:  2015-01-09       Impact factor: 4.288

Review 4.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

5.  Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

Authors:  Abby B Siegel; Emil I Cohen; Allyson Ocean; Deborah Lehrer; Alec Goldenberg; Jennifer J Knox; Helen Chen; Sean Clark-Garvey; Alan Weinberg; John Mandeli; Paul Christos; Madhu Mazumdar; Elizabeta Popa; Robert S Brown; Shahin Rafii; Jonathan D Schwartz
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

Review 7.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

8.  SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.

Authors:  Andrew X Zhu; Olivier Rosmorduc; T R Jeffry Evans; Paul J Ross; Armando Santoro; Flair Jose Carrilho; Jordi Bruix; Shukui Qin; Paul J Thuluvath; Josep M Llovet; Marie-Aude Leberre; Markus Jensen; Gerold Meinhardt; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2014-12-29       Impact factor: 44.544

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.

Authors:  Han Chong Toh; Pei-Jer Chen; Brian I Carr; Jennifer J Knox; Sharlene Gill; Peter Ansell; Evelyn M McKeegan; Barry Dowell; Michelle Pedersen; Qin Qin; Jiang Qian; Frank A Scappaticci; Justin L Ricker; Dawn M Carlson; Wei Peng Yong
Journal:  Cancer       Date:  2012-07-25       Impact factor: 6.860
View more
  9 in total

1.  Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.

Authors:  Seunghyun Lee; Jung Hoon Kim; Jae Hwan Lee; Jeong Hwa Lee; Joon Koo Han
Journal:  Eur Radiol       Date:  2017-07-27       Impact factor: 5.315

Review 2.  Evolving role of Sorafenib in the management of hepatocellular carcinoma.

Authors:  Ioannis A Ziogas; Georgios Tsoulfas
Journal:  World J Clin Oncol       Date:  2017-06-10

Review 3.  Tumor Microenvironment, a Paradigm in Hepatocellular Carcinoma Progression and Therapy.

Authors:  Maryam Tahmasebi Birgani; Vinicio Carloni
Journal:  Int J Mol Sci       Date:  2017-02-14       Impact factor: 5.923

4.  Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells.

Authors:  Jing Wang; Peng Sun; Yijun Chen; Hequan Yao; Shuzhen Wang
Journal:  Sci Rep       Date:  2018-07-19       Impact factor: 4.379

5.  Dandelion Polysaccharide Exerts Anti-Angiogenesis Effect on Hepatocellular Carcinoma by Regulating VEGF/HIF-1α Expression.

Authors:  Feng Ren; Kaixuan Wu; Yun Yang; Yingying Yang; Yuxia Wang; Jian Li
Journal:  Front Pharmacol       Date:  2020-04-08       Impact factor: 5.810

6.  First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.

Authors:  Wenfeng Liu; Bing Quan; Shenxin Lu; Bei Tang; Miao Li; Rongxin Chen; Zhenggang Ren; Xin Yin
Journal:  Front Oncol       Date:  2021-12-24       Impact factor: 6.244

Review 7.  Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma.

Authors:  Yuanfei Lu; Na Feng; Yongzhong Du; Risheng Yu
Journal:  Nanomaterials (Basel)       Date:  2022-08-17       Impact factor: 5.719

8.  Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance.

Authors:  Wei Wang; Min Zhang; Yan Peng; Jie He
Journal:  Med Sci Monit       Date:  2017-10-05

Review 9.  Liver, Tumor and Viral Hepatitis: Key Players in the Complex Balance Between Tolerance and Immune Activation.

Authors:  Matti Sällberg; Anna Pasetto
Journal:  Front Immunol       Date:  2020-03-27       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.